Widely Used Painkiller Paracetamol Not Linked to Neurodevelopmental Disorders, Major Review Finds
Table of Contents
A comprehensive analysis of existing research indicates that concerns about a link between prenatal paracetamol (acetaminophen) exposure and neurodevelopmental disorders like ADHD and autism are largely unfounded, stemming from studies plagued by methodological flaws.
Recent anxieties surrounding the safety of paracetamol during pregnancy were ignited in September 2025 when the President of the United states publicly advised against using Tylenol (acetaminophen) due to perceived autism risks in children. However,this recommendation sharply contrasts with the consensus of medical authorities and health regulators globally,who continue to affirm the drug’s safety based on current evidence.
scrutinizing the Evidence: A BMJ Inquiry
Researchers publishing in the british Medical Journal (BMJ) undertook a rigorous assessment of the quality, validity, and potential biases within existing studies exploring a connection between maternal paracetamol use and the development of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in offspring. The investigation revealed meaningful shortcomings in much of the available research.
Methodological Concerns Undermine Previous Findings
The review team systematically searched major databases – including Embase, Medline, Cochrane Database of Systematic Reviews, PsycINFO, Epistemonikos, and sources of gray literature – to identify relevant systematic reviews and meta-analyses. Nine systematic reviews, encompassing 40 primary studies and four meta-analyses, met the inclusion criteria for analysis. However, the quality assessment exposed critical gaps.
“Most reviews lacked registered protocols,comprehensive search strategies,and clear justifications for excluding certain studies,” the researchers found. Furthermore, risk of bias assessments were frequently incomplete or absent, and standardized evaluation tools like ROBINS-I or ROBINS-E were not utilized. Statistical methods were often inadequate,with only a single review pooling adjusted estimates.Consequently, the overall level of confidence in the findings was rated as low in two assessments and extremely low in seven.
Sibling Studies Reveal a Different Picture
While many studies initially reported positive associations between prenatal acetaminophen exposure and adverse neurodevelopmental outcomes – with odds ratios for ADHD ranging from 1.2 to 1.4 and weaker links to ASD – these associations largely disappeared when researchers employed sibling-controlled analyses. These analyses account for shared genetic and familial factors, suggesting that observed relationships are more likely attributable to confounding variables rather than a direct causal effect of the drug. The high degree of overlap between primary studies (23) further complicated interpretation.
Notably, seven of the reviewed studies explicitly cautioned against drawing causal conclusions, emphasizing that apparent risks may be a result of study bias and design limitations, rather than genuine biological effects.
A Weak, Non-Causal Link
The collective evidence points to a weak, non-causal relationship between maternal acetaminophen use during pregnancy and neurodevelopmental disorders in children.
Here’s a news report answering the “Why, Who, What, and How” questions:
Why: Concerns arose after the U.S. President advised against using acetaminophen (Tylenol) during pregnancy, citing potential links to autism in children. This sparked widespread anxiety despite existing medical consensus.
Who: Researchers from the British Medical Journal (BMJ) conducted a comprehensive review of existing studies. The U.S. President’s statement initially fueled the concerns, while medical authorities
